Has John Friedewald, MD received payments from drug or device companies?

Yes. Drug and device makers reported $93,169 in general payments to John Friedewald, MD across 60 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean John Friedewald, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about John Friedewald, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

John Friedewald, MD

Nephrology · Chicago, ILNPI 1508801093

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (56.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Sanofi-aventis U.S. LLC accounts for 60.4% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2024 at $29,815 and has fallen 63.3% since, to $10,931 in 2025. Among nephrology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$93,169in general payments, 2019–2025

Across 60 payments — averaging $1552.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi-aventis U.S. LLC$56K
Veloxis Pharmaceuticals, Inc.$9K
Novartis$7K
Mallinckrodt Hospital Products Inc.$7K
Sanofi$6K
Vertex$5K
plus $2K from 6 others

$378,946in research payments, 2019–2025

Across 160 payments — averaging $2368.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Regeneron$196K
CSL Behring$90K
AbbVie$57K
Shire North American Group Inc$32K
Takeda Pharmaceuticals U.S.A., Inc.$5K

What the payments were for

Consulting fees$33,42236%
Speaking & faculty fees$52,45256%
Travel & lodging$4,8865%
Food & beverage$2,3543%
Education$550%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi-aventis U.S. LLC	32	$56,246
Veloxis Pharmaceuticals, Inc.	6	$8,938
Novartis	2	$7,310
Mallinckrodt Hospital Products Inc.	2	$6,882
Sanofi	3	$6,329
Vertex	6	$5,081
One Lambda, Inc.	2	$2,049
AstraZeneca	2	$185
Amgen	2	$55
Akebia Therapeutics Inc	1	$40
Gilead	1	$31
Eurofins Viracor, LLC	1	$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

THYMOGLOBULIN$41,047
REZUROCK$10,523
Envarsus$8,847
UVADEX$6,750
SOLIRIS$150
TERLIVAZ$132
TZIELD$125

How this compares

$93,169 in reported general payments places this provider in the 95th percentile of 524 nephrology providers in Illinois.

See all nephrology providers in Illinois →

Medicare billing

Part B allowed, 2024

$70,492

Medicare patients

252

Services billed

866

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Envarsus XrTacrolimus	26	$44,080
CellceptMycophenolate Mofetil	18	$28,934
Valganciclovir Hcl	27	$11,856
Tacrolimus	58	$9,792
Mycophenolate Mofetil	29	$9,657
Atovaquone	11	$9,454
Entecavir	16	$3,196
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim	447	$2,713
Cinacalcet Hcl	19	$2,266
Nifedipine ErNifedipine	35	$1,928
Prednisone	157	$1,168
Bumetanide	14	$765
Famotidine	55	$688
Carvedilol	72	$601
Amlodipine Besylate	59	$376

Paid to pharmacies, not to this prescriber.

Other nephrology in Chicago

Myles WolfChicago$2.1M
Susan QuagginChicago$262K
Nicole StankusChicago$235K
Marco BonillaChicago$148K
Lorenzo GallonChicago$120K
Vikram AggarwalChicago$117K
Jay KoynerChicago$113K
Jose ArrudaChicago$107K
Casey GashtiChicago$74K
Amr YafiChicago$71K

See the full list for Illinois →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →